Month: January 2024

HOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) — U.S. Energy Corp. (Nasdaq: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in the operation of high-quality producing oil and natural gas assets, today announced it had completed a series of non-core asset divestitures. HIGHLIGHTSAll-cash proceeds of approximately $7.2 million; Divested assets averaged approximately 200 barrels of oil equivalent per day (83% oil) from July-September 2023, or 12% of USEG total production over the same period; All proceeds used to reduce existing debt, leaving USEG materially debt-free1; No changes to the Company’s existing $20.0 million borrowing base; Represents the majority of USEG’s non-operated assets.MANAGEMENT COMMENTARY “Throughout the fourth quarter, we executed on a series of asset divestitures representing the...

Second Tier-1 Customer to Use Multiple Akoustis 5 GHz and 6 GHz Wi-Fi 7 Filters for a 4X4 MU-MIMO AP Platform Has Received Prototype Orders to Enable Production Ramp in the Second Half Calendar Year 2024Charlotte, N.C., Jan. 10, 2024 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that five of its patented XBAW® filters are being designed into a new quad-band enterprise Wi-Fi access point (AP) platform.  The new design will use multiple Akoustis wideband and narrowband Wi-Fi XBAW® coexistence filters in the 5 and 6 GHz bands. These filters are being utilized in a 4X4 multi-user, multiple-in-multiple-out (MU-MIMO) quad-band Wi-Fi...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (NEO:ABXX)(OTCQX:ABXXF) (“Abaxx Tech” or the “Company”), a financial software and market infrastructure company and majority shareholder of Abaxx Singapore Pte. Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, is pleased to announce that Abaxx Singapore has closed its best efforts equity private placement as previously announced on January 3, 2024 (the “Offering”) for gross proceeds of US$27,323,013. The Offering consisted of the issuance of 953,787 preferred shares (the “Preferred Shares”) to strategic partners and 4,837,392 ordinary...

– ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 – – Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach – – ATI-1777 Was Well Tolerated – WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (AD) (ATI-1777-AD-202; NCT05432596). ATI-1777 was generated from Aclaris’ proprietary KINect® drug discovery platform. ATI-1777-AD-202 was a Phase 2b, multicenter, randomized, double-blind, vehicle-controlled,...

New patient enrollment sites accelerating screening activity Screening activity exceeding 100 patients per week Approaching interim enrollment target of 90 patientsTORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment:Initiated 2024 with robust site activity to start the new year:Enrolled patient 82 during the first week of January. Post-holiday break, strong screening activity resumed with more than 100 patients screened per week.Closing in on the...

— Reported Unaudited Total Revenues of Between $72 Million – $74 Million in the Fourth Quarter of 2023 — — Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million — — 2024 Key Priorities Include Accelerating Revenue in Key European Launch Markets, Retaining IPE Market Leadership in the US and Maximizing Patient Uptake in Rest of World (RoW) Through Partnerships — — Company Announces Plan to Initiate Share Repurchase Program of Up to $50 Million — — Amarin to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 — DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited...

Figure 1Post-Tax NPV SensitivityFigure 2Post-Tax IRR SensitivityVANCOUVER, British Columbia, Jan. 10, 2024 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | NASDAQ:AMLI | Frankfurt:5LA1) is pleased to announce the results of its updated Preliminary Economic Assessment (“PEA”) for the Falchani Lithium (“Falchani”) project located in Puno, southwestern Peru. This independent, updated PEA was completed by DRA Global following the updated mineral resource estimate recently completed by Stantec Consulting Services Ltd. (“Stantec” – see news release dated December 15, 2023). The updated PEA demonstrates that with low initial capex, the Falchani project has the potential to become a substantial, low-cost, long-life producer of high purity Lithium Carbonate (“LCE” or “Li2CO3”)...

Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy HOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the first dose cohort of the dose escalation portion of its Phase 1 clinical trial of BP1002 evaluating the ability of BP1002, a liposomal Bcl-2 nanoparticle antisense, for the treatment of refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients.   “We are delighted to safely complete this first dose cohort and to advance BP1002 into the next cohort as it brings us one step closer to providing...